TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 3.4% – Should You Sell?

TransCode Therapeutics Inc. (NASDAQ:RNAZ)’s share price dropped 3.4% during trading on Friday . The company traded as low as $2.87 and last traded at $2.87. 38,971 shares traded hands during trading, an increase of 37% from the average daily volume of 28,420 shares. The stock had previously closed at $2.97.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

TransCode Therapeutics Stock Down 3.4%

The company’s fifty day simple moving average is $5.78 and its 200 day simple moving average is $7.36. The firm has a market capitalization of $3.04 million, a PE ratio of -0.05 and a beta of 1.24.

TransCode Therapeutics (NASDAQ:RNAZ) last posted its quarterly earnings data on Friday, August 14th. The company reported ($7.17) earnings per share for the quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.